ABIVAX Societe Anonyme

Shares of European biotech Abivax SA have surged almost 1,400% year to date on the Paris exchange, with its market capitalization now above EUR7.5 billion. Investors are buying the stock, considering the company an attractive takeover target amid successful trials of its experimental drug, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-12-04/europe-s-biotech-standout-faces-crucial-year-after-1-300-rally">writes</a>. Wall Street remains <a href="https://www.marketwatch.com/investing/stock/abvx/analystestimates?mod=mw_quote_tab">bullish</a>&nbsp;on the name.

French biotech Abivax rides upbeat data, takeover speculation to 1,400% YTD gain

CRH plc

Vertiv Holdings Co

Alnylam Pharmaceuticals, Inc.

Construction company CRH, data center equipment maker Vertiv Holdings, biotech Alnylam Pharmaceuticals and investment firm Ares Management are prime candidates for inclusion in the S&amp;P 500 Index during its quarterly review in December, Barron's <a href="https://www.barrons.com/articles/crh-vertiv-ares-alnylam-sp500-stocks-rebalancing-10a39a07?mod=RTA">writes.</a>

The S&amp;P 500 is gearing up for a rebuild: which companies will make the move to the "big leagues"?

Palantir Technologies Inc.

ARK Invest experts are sure that the market is trying in vain to apply the logic of dotcoms to AI

Cathie Wood: talk of an AI bubble is misleading investors

Olema Pharmaceuticals, Inc.

Roche Holding AG

Shares of Olema Pharmaceuticals, a small-cap maker of cancer drugs, <a href="https://finance.yahoo.com/quote/OLMA/">soared</a>&nbsp;almost 200% last week, November 18-24. Investors were <a href="https://www.roche.com/media/releases/med-cor-2025-11-18">reacting</a>&nbsp;to positive news on clinical trials from Swiss pharma giant Roche. Olema is advancing a therapy with a similar mechanism of action, meaning Roche’s success has reduced the perceived risks of investing in Olema, Freedom Broker explains. Against this backdrop, at least two Wall Street analysts have <a href="https://finance.yahoo.com/quote/OLMA/">raised</a>&nbsp;their target price on Olema shares.

Oncology drugmaker Olema triples in a week after latest Roche data eases sector risks

Vertex Pharmaceuticals Incorporated

Techno-billionaires from Silicon Valley are actively <a href="https://oninvest.com/article/magnaty-kremnievoj-doliny-delaut-stavki-na-omolozenie-mozno-li-na-etom-zarabotat">investing</a> in finding new ways to extend life. However, they are not only concerned about this - in San Francisco, with the support of OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong, a startup called Preventive has been secretly <a href="https://www.wsj.com/tech/biotech/genetically-engineered-babies-tech-billionaires-6779efc8">working</a> <a href="https://www.preventive.bio/blog/announcing-preventive">for</a> six months to create genetically "improved" babies using the latest DNA editing technologies. And he's not the only one. The idea is a noble one - to rid people of genetic diseases, but critics fear both failure and success of this venture.

Human 2.0: where Silicon Valley's attempt to rewrite DNA is headed

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Akeso, Inc.

Legend Biotech Corporation

3SBio Inc.

BeOne Medicines AG

Innovent Biologics, Inc.

In 2025, biotech companies from China are likely to renew the record for the sixth consecutive year in terms of the volume of deals with Western pharma giants actively buying up the rights to develop and sell Chinese drugs. Ilya Zubkov, Freedom Broker's senior analyst for the healthcare sector, has selected seven companies that investors looking to capitalize on the growth of Chinese biotech should pay attention to.

China's biotech companies are booming. How to capitalize on it? 

BillionToOne

BillionToOne IPO: Molecular diagnostics company debuts on the Nasdaq

Evommune, Inc.

The market value of the company, based on the listing results, was estimated at more than $480 billion

Evommune IPO: shares in atopic dermatitis treatment developer become available

Sarepta Therapeutics, Inc.

Shares of Sarepta Therapeutics, a mid-cap developer of therapies for rare diseases, <a href="https://finance.yahoo.com/quote/SRPT/">plummeted</a>&nbsp;nearly 40% in post-market trading yesterday, November 3, after the company <a href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2025-financial">announced</a>&nbsp;that it had failed extended trials for <a href="https://www.sarepta.com/products-pipeline/products">two of its main drugs</a>. Both are already available in the U.S., but the new data <a href="https://www.bloomberg.com/news/articles/2025-11-03/sarepta-says-older-duchenne-drugs-failed-confirmatory-trial">could</a>&nbsp;prompt regulators to reconsider their approval.

Sarepta plunges 40% after-hours as muscle disease drugs fail confirmatory trial

MapLight Therapeutics, Inc.

Navan, Inc.

OpenAI is preparing one of the most expensive public offerings in history, and one of the world's largest manufacturers of medical devices Medline has applied for a placement with a possible valuation of up to $ 50 billion. In addition, after a long pause is observed a revival of the British IPO market, but so far the dynamics of shares of recently listed companies remains ambiguous. The main events on the IPO market for the week are in our selection.

OpenAI's $1 trillion listing and a rebound in the UK market: highlights of IPOs by Nov. 2

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Shares of biotech company Viking Therapeutics could triple, according to Canaccord Genuity, which in a <a href="https://www.cnbc.com/2025/10/29/biggest-analyst-calls-wednesday-include-nvidia-apple-tesla-datadog.html">coverage initiation</a> called the firm "one of the leading biotech companies in the obesity drug development space," now <a href="https://oninvest.com/article/gde-investoram-iskat-potencial-nyj-hit-na-rynke-preparatov-ot-lisnego-vesa">dominated</a>&nbsp;by Novo Nordisk and Eli Lilly.

Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside

Avidity Biosciences, Inc.

Novartis AG

Shares of Avidity Biosciences, a small developer of therapies for rare diseases including Duchenne muscular dystrophy, jumped more than 40% yesterday, October 27, to an all-time high. Investors reacted to news that Switzerland’s Novartis <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html">plans</a>&nbsp;to acquire the company at a premium to the market. The move sends a signal to investors in small-cap biotech: pharma majors increasingly prefer to buy externally developed assets rather than build them in-house. More transactions can be expected in the coming months, Noble Capital Markets <a href="https://www.channelchek.com/news-channel/novartis-12-billion-avidity-acquisition-strengthens-its-rare-disease-pipeline-amid-pharma-tariff-uncertainty">said</a>&nbsp;in a post.

Biotechnology